Ernexa Therapeutics Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 16 →Insiders1 insider bought $2.0M in 1 open-market buy. No sales.→HoldersCitadel 1.3%Vanguard Fiduciary Trust 0.7%Dauntless Investment 0.5%→Financing →PeersClosest companies: PHIO, VIVS, ZSQR→
From the filings
Figures
- Net income
- −$12.3Mlast 12 months
- Operating cash flow
- −$7.2Mlast 12 months
- Cash and equivalents
- $5.0Mat the last balance sheet
- Shares outstanding
- 1.2M shareson issue